NO992577L - Transfeksjonsblanding for anvendelse ved genterapi og som kombinerer en rekombinant virus som inkorporerer en exogen nukleinsyre, med et ikke-viralt, ikke-plasmidisk transfeksjonsmiddel - Google Patents

Transfeksjonsblanding for anvendelse ved genterapi og som kombinerer en rekombinant virus som inkorporerer en exogen nukleinsyre, med et ikke-viralt, ikke-plasmidisk transfeksjonsmiddel

Info

Publication number
NO992577L
NO992577L NO992577A NO992577A NO992577L NO 992577 L NO992577 L NO 992577L NO 992577 A NO992577 A NO 992577A NO 992577 A NO992577 A NO 992577A NO 992577 L NO992577 L NO 992577L
Authority
NO
Norway
Prior art keywords
transfection
plasmidic
viral
nucleic acid
gene therapy
Prior art date
Application number
NO992577A
Other languages
English (en)
Norwegian (no)
Other versions
NO992577D0 (no
Inventor
Nathalie Aubailly
Patrick Benoit
Didier Branellec
Aude Le Roux
Abderrahim Mahfoudi
Nathalie Ratet
Original Assignee
Rhone Poulenc Rorer Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone Poulenc Rorer Sa filed Critical Rhone Poulenc Rorer Sa
Publication of NO992577D0 publication Critical patent/NO992577D0/no
Publication of NO992577L publication Critical patent/NO992577L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/10—Vectors comprising a non-peptidic targeting moiety
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/40—Vectors comprising a peptide as targeting moiety, e.g. a synthetic peptide, from undefined source
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
    • C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
    • C12N2810/859—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from immunoglobulins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Plant Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NO992577A 1996-11-29 1999-05-28 Transfeksjonsblanding for anvendelse ved genterapi og som kombinerer en rekombinant virus som inkorporerer en exogen nukleinsyre, med et ikke-viralt, ikke-plasmidisk transfeksjonsmiddel NO992577L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9614693A FR2756491B1 (fr) 1996-11-29 1996-11-29 Composition transfectante utile en therapie genique associan t a un virus recombinant incorporant un acide nucleique exog ene, un agent de transfection non viral et non plasmidique
PCT/FR1997/002157 WO1998023765A1 (fr) 1996-11-29 1997-11-28 Composition transfectante utile en therapie genique associant a un virus recombinant incorporant un acide nucleique exogene, un agent de transfection non viral et non plasmidique

Publications (2)

Publication Number Publication Date
NO992577D0 NO992577D0 (no) 1999-05-28
NO992577L true NO992577L (no) 1999-07-28

Family

ID=9498192

Family Applications (1)

Application Number Title Priority Date Filing Date
NO992577A NO992577L (no) 1996-11-29 1999-05-28 Transfeksjonsblanding for anvendelse ved genterapi og som kombinerer en rekombinant virus som inkorporerer en exogen nukleinsyre, med et ikke-viralt, ikke-plasmidisk transfeksjonsmiddel

Country Status (13)

Country Link
EP (1) EP0948636A1 (fr)
JP (1) JP2001514485A (fr)
KR (1) KR20000057307A (fr)
AU (1) AU737846B2 (fr)
BR (1) BR9713434A (fr)
CA (1) CA2272637A1 (fr)
CZ (1) CZ188299A3 (fr)
FR (1) FR2756491B1 (fr)
HU (1) HUP9904201A3 (fr)
IL (1) IL130053A0 (fr)
NO (1) NO992577L (fr)
SK (1) SK70999A3 (fr)
WO (1) WO1998023765A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100764890B1 (ko) * 2005-11-14 2007-10-09 한국화학연구원 폴리에틸렌이민과 인지질을 접합하여 제조된 리포솜을이용한 항암주사제 및 이의 제조방법
US9273300B2 (en) 2007-02-07 2016-03-01 Strike Bio, Inc Methods and compositions for modulating sialic acid production and treating hereditary inclusion body myopathy
KR100980395B1 (ko) 2008-06-27 2010-09-07 재단법인서울대학교산학협력재단 비-바이러스성 유전자 전달체용 중합체/유전자 복합체
JP5944622B2 (ja) * 2011-04-08 2016-07-05 株式会社ブリヂストン 遺伝子導入剤組成物
KR102101210B1 (ko) 2012-03-02 2020-04-16 고쿠리츠켄큐카이하츠호진 카가쿠기쥬츠신코키코 기능성 핵산 분자의 구축법, 및 상기 방법에 사용하는 핵산 조합물

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2646161B1 (fr) * 1989-04-17 1991-07-05 Centre Nat Rech Scient Nouvelles lipopolyamines, leur preparation et leur emploi
US5552309A (en) * 1994-09-30 1996-09-03 Indiana University Foundation Use of polyols for improving the introduction of genetic material into cells
FR2727679B1 (fr) * 1994-12-05 1997-01-03 Rhone Poulenc Rorer Sa Nouveaux agents de transfection et leurs applications pharmaceutiques
FR2730637B1 (fr) * 1995-02-17 1997-03-28 Rhone Poulenc Rorer Sa Composition pharmaceutique contenant des acides nucleiques, et ses utilisations
FR2741066B1 (fr) * 1995-11-14 1997-12-12 Rhone Poulenc Rorer Sa Nouveaux agents de transfection et leurs applications pharmaceutiques

Also Published As

Publication number Publication date
HUP9904201A3 (en) 2002-01-28
HUP9904201A1 (hu) 2000-04-28
CZ188299A3 (cs) 1999-09-15
FR2756491A1 (fr) 1998-06-05
EP0948636A1 (fr) 1999-10-13
SK70999A3 (en) 2000-03-13
FR2756491B1 (fr) 1999-01-08
IL130053A0 (en) 2000-02-29
WO1998023765A1 (fr) 1998-06-04
KR20000057307A (ko) 2000-09-15
NO992577D0 (no) 1999-05-28
JP2001514485A (ja) 2001-09-11
AU7401098A (en) 1998-06-22
CA2272637A1 (fr) 1998-06-04
AU737846B2 (en) 2001-08-30
BR9713434A (pt) 2000-02-01

Similar Documents

Publication Publication Date Title
FR2704234B1 (fr) Virus recombinants, preparation et utilisation en therapie genique.
FR2712603B1 (fr) Virus recombinants, préparation et utilisation en thérapie génique.
EP0786989A4 (fr) Vesicules lipidiques contenant la proteine rep de virus adeno-associe pour integration transgenique et therapie genique
DE69634300D1 (de) Gentherapie mit hilfe von schaf-adenoviralen vektoren
IL181695A0 (en) Methods for cultivating cells and propagating viruses
FR2718150B1 (fr) Virus recombinants, préparation et utilisation en thérapie génique.
WO2006058231A3 (fr) Vecteurs viraux
CA2364499A1 (fr) Transduction de cellules ressemblant a des fibroblastes ou a des macrophages et moyens a cet effet
AU7077898A (en) Recombinant vectors derived from adeno-associated virus suitable for gene therapy
FR2712602B1 (fr) Virus recombinants, préparation et utilisation en thérapie génique.
NO992577D0 (no) Transfeksjonsblanding for anvendelse ved genterapi og som kombinerer en rekombinant virus som inkorporerer en exogen nukleinsyre, med et ikke-viralt, ikke-plasmidisk transfeksjonsmiddel
NO973724L (no) Medisinske kombinasjoner anvendelige for in vivo eksogen transfeksjon og ekspresjon
NO981322D0 (no) Farmasöytiske preparater for bruk ved nukleinsyretransfeksjon, og deres anvendelse
AU4089899A (en) Stable envelope proteins for retroviral, viral and liposome vectors and use in gene and drug therapy
WO1999047678A3 (fr) Plasmides d'interferon alpha, systemes d'administration et procedes de fabrication desdits plasmides
NO974179L (no) Rekombinante viruser som uttrykker lecitin-kolesterol-acyltransferase, og anvendelse derav i genterapi
AU4425397A (en) Antisense gene therapy for rna viruses
EP0763205A4 (fr) Sequences d'acides nucleiques regulant l'expression de genes specifiques aux poumons
WO2000062815A3 (fr) Nouvelle composition pharmaceutique utilisable en therapie genique
FI971377A (fi) Adenovirusperäisiä virusvektoreita, joissa on kaksi terapeuttista geeniä: itsemurha- ja immuunistimuloiva geeni
FR2717495B1 (fr) Virus recombinants, préparation et utilisation en thérapie génique.
NO963806L (no) Rekombinante viruser som koder for en glutamat-dekarboksylase (GAD)aktivitet
PT1016714E (pt) Novo adn plasmidico que compreende adn do gene reporter e sua utilizacao
EP1134285A4 (fr) Fragment d'acide nucleique, vecteur de recombinaison contenant ledit fragment et procede permettant d'activer l'expression d'un gene de structure au moyen de ce dernier
ZA971070B (en) Transfectant composition useful in gene therapy asA water control gate. sociating with a recombinant virus incorporating an exogenous nucleic acid and a non-viral and non-plasmid transfection agent.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application